Adverse effects of immune checkpoint inhibitor therapies on right ventricular function and pulmonary arterial dilatation
Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events. We retrospectively describe the impact of immune checkpoi...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2021-02-01
|
| Series: | Pulmonary Circulation |
| Online Access: | https://doi.org/10.1177/2045894021992236 |